|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.62 / 5.79|
Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.
Here's a technical look at how to trade several under-$10 stocks that are within range of triggering big breakouts.
Nymox Pharmaceuticals (NYMX) announced that a recent study on fexapotide, the company's lead drug for enlarged prostates and prostate cancer, was successful.
Nymox Pharmaceuticals (NYMX) is working to get its fexapotide drug approved and may partner with a larger company to help market the medication.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox...
Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%
Insiders at these companies have been scooping up shares of their own companies lately.
These under-$10 biotech stocks are within range of triggering breakout trades.
Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.